Metastatic renal cell carcinoma (mRCC) has seen increased treatment options in recent years, including immunotherapy (IO) combinations paired with tyrosine kinase inhibitors (TKI). A meta-analysis of ...
Comparing the effectiveness of IO-based combination regimens as first-line treatment for advanced clear-cell renal cell carcinoma (ccRCC). This is an ASCO Meeting Abstract from the 2025 ASCO ...
First-line IO-based combinations provide clinically meaningful survival in sRCC, with outcomes affected by sex, metastatic sites, and IMDC risk. This RWE may support a tailored therapeutic approach on ...
Credit: Getty Images Investigators report findings from a real-world study that included 389 patients with brain metastases from renal cell carcinoma. First-line treatment with immuno-oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results